| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 浙江向日葵大健康科技股份有限公司成立于2005年,于2010年8月在深圳创业板上市。公司致力于医药、大健康和高科技产业投资,未来将打造医药创新、医疗器械和医药服务的大健康产业集群和TMT方向的高科技产业集群,把握中国经济转型的机遇。公司愿景是“健康承载梦想,行动成就未来”。公司下属子公司贝得药业为高新技术企业,旗下4条生产线均已通过国家GMP认证,共计取得了20个制剂、原料药生产批准文件,其中2个品种被列为甲类医保目录,3个品种被列入国家基药目录,主导产品涵盖抗感染药物、抗高血压等领域,远销至印度、韩国、西班牙、巴基斯坦等国家。主营业务：抗感染、抗高血压等药物的研发、生产和销售。主要产品：克拉霉素原料药、克拉霉素片、阿奇霉素分散片、注射用阿奇霉素、罗红霉素胶囊、拉西地平分散片、辛伐他汀片、注射用奥美拉唑钠、注射用法莫替丁。 | ||||||||||||||||||||||||
| Main Business | 抗感染、抗高血压等药物的研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 吴少钦 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 李岚 | ||||||||||||||||||||||||
| Solicitors | 上海市锦天城律师事务所 | ||||||||||||||||||||||||
| Auditors | 立信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0575-88919159 | ||||||||||||||||||||||||
| Fax No | 0575-88919159 | ||||||||||||||||||||||||
| Website | www.sunowe.com | ||||||||||||||||||||||||
| michelle.li@sunowe.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 27/08/2010 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.017 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 0.527 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 4.222B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |